Pharmaceutical

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Nov 5, 2024 - 06:00
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.
Read the original article

Tags:

Previous Article

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

Next Article

Injectables manufacturing ushers in a new era of accessibility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer

ImmunoPrecise and Biotheus partner on bispecific antibo...

Oct 4, 2024

STAT+: Federal Medicaid officials cajole states to auto-enroll beneficiaries as huge coverage losses loom

STAT+: Federal Medicaid officials cajole states to auto...

Mar 19, 2023

STAT+: Senate still hasn’t made hard decisions on lowering insulin costs

STAT+: Senate still hasn’t made hard decisions on lower...

Apr 19, 2023